Company profile
The company is characterized by the development of pediatric drugs, mainly engaged in the research and development, production and sales of proprietary Chinese medicines and chemicals, covering respiratory system, digestive system, systemic anti-infection and other fields of application. The company's main products are respiratory preparations such as Xiaoer Feirre Kechuan granules, Bromohexine Hydrochloride for injection, compound Banlangen granules, Keke tablets, etc.; digestive system preparations such as omeprazole enteric-coated capsules, Changyanning (capsules and granules), omeprazole sodium for injection, diisopropylamine gluconate sodium dichloroacetate for injection, cefixime dispersible tablets, aztreonam for injection, clindamycin phosphate for injection, etc. And a small number of gynecological drugs, cardiovascular system drugs, neurological system drug preparation products.
The highlight of the company
(1) the company is characterized by the development of pediatric drugs, mainly proprietary Chinese medicine, rapid development of chemicals, and respiratory system drugs, digestive system drugs and systemic anti-infective drugs as the main product areas. Up to now, the company has 295 drug approval numbers, 57 kinds of products have entered the national essential drug catalogue, 96 kinds of products have entered the national medical insurance catalogue, among which chemical tablets and nimesulide sustained-release capsules are exclusive dosage forms. Xiaoer Feirre Kechuan granule, Changyanning capsule and Changyanning granule are the exclusive specification products. At present, children's lung heat cough and asthma and Changyanning products rank second in the market share of similar products in OTC.
(2) in the field of pediatric medicine, the company has 24 varieties of high-quality oral pediatric drugs, including Xiaoer Feirre Kechuan granule, Changyanning granule, cefixime dispersible tablet, Xiaoer aminjin Huangmin granule, infantile cough syrup, Xiaoer Qingyan granule, etc. Among them, there are 17 varieties of oral pediatric drugs (excluding adult and child double cross-products). It covers the use of drugs in children's respiratory system, digestive system and systemic anti-infective drugs, forming a relatively complete pediatric drug product system. According to the characteristics of drugs and the needs of different age groups, the company has invested in the construction of 16 types of pharmaceutical preparation production lines, such as tablets, capsules, granules, soft capsules, dry suspensions, oral liquids, powders, pills, powder injections, freeze-dried powder injections, tinctures and so on.
(3) the company has more drugs included in the national essential drug catalogue and national medical insurance catalogue, as well as a relatively complete product system with rich dosage forms. The company can adjust the product and product mix in real time according to market demand, give full play to the scale advantages of production, sales and brand promotion, and maximize to meet the needs of the market and patients.
